You are here

  • Home
  • Archive
  • Volume 105, Issue 7
  • Quality of life in patients with uveitis: data from the ULISSE study (Uveitis: cLInical and medico-economic evaluation of a Standardised Strategy for the Etiological diagnosis)

Article Text

Article menu
Download PDFPDF
Clinical science
Quality of life in patients with uveitis: data from the ULISSE study (Uveitis: cLInical and medico-economic evaluation of a Standardised Strategy for the Etiological diagnosis)
  1. Pierre-jean Bertrand1,
  2. Yvan Jamilloux2,
  3. Laurent Kodjikian3,
  4. Marie-Helene Errera4,
  5. Laurent Perard5,
  6. Gregory Pugnet6,
  7. Nathalie Tieulie7,
  8. Marc Andre8,
  9. Philip Bielefeld9,
  10. Alain M Bron10,
  11. Evelyne Decullier11,
  12. Sylvie Bin11,
  13. Pascal Seve1
  1. 1 Internal Medicine, Hospices Civils De Lyon, Lyon, France
  2. 2 Internal Medicine, Hopital De La Croix-Rousse,Lyon, France
  3. 3 Ophthalmology, Croix Rousse University Hospital, Hospices Civils De Lyon, Lyon, France
  4. 4 Department of Ophthalmology, Quinze-Vingts Hospital, Paris, France
  5. 5 Internal Medicine, Edouart Herriot University Hospital, Hospices Civils De Lyon, Lyon, France
  6. 6 Department of Internal Medicine, Purpan University Hospital, Toulouse, France
  7. 7 Deparment of Rheumatology, Archet Hospital, Nice, France
  8. 8 Médecine Interne, Hopital Gabriel Montpied, Clermont-Ferrand,France
  9. 9 Médecine Interne, Centre Hospitalier Universitaire De Dijon, Dijon, France
  10. 10 Ophthalmology, University Hospital, Dijon, France
  11. 11 Pole IMER Lyon, Hospices Civils de Lyon, Lyon, France
  1. Correspondence to Pascal Sève, Department of Internal Medicine, Hôpital De La Croix Rousse, 103 Grande Rue De La Croix-Rousse, Lyon 69004, France; pascal.seve{at}chu-lyon.fr

Abstract

Aims To assess vision-related (VR-QOL) and health-related quality of life (HR-QOL) in a large series of patients with de novo uveitis at baseline and 6-month follow-up.

Methods Non-inferiority, prospective, multicentre, cluster randomised controlled trial registered under the Unique Identifier: NCT01162070. VR-QOL and HR-QOL were assessed by the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) and the Medical Outcomes Study 36-item Short Form Survey (SF-36).

Results At inclusion, 466 patients completed the VFQ-25. The mean composite score was 80.0 (±16.7). In multivariate analysis, higher age, female sex and insidious onset were significantly associated with lower QOL. At 6 months, 138 patients completed the VFQ-25, with a significantly higher mean composite score of 82.6 (±16.7). SF-36 mental component was 42.9 (±11.3) and physical component was 47.2 (±8.5) at inclusion (n=425). HR-QOL improvement at 6 months was not clinically significant.

Conclusion QOL seems relatively well preserved in this cohort; only VR-QOL improved significantly at 6 months, especially in patients with low initial visual acuity.

  • Inflammation
  • Immunology
  • Vision

https://doi.org/10.1136/bjophthalmol-2020-315862

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors BPJ analysed the data, wrote the original draft, revised and validated the paper. JY designed the study, monitored data collection, drafted, revised and validated the paper. KL supervised the study, monitored data collection, analysed the data, revised and validated the paper. EMH monitored data collection, revised and validated the paper. PL monitored data collection, revised and validated the paper. PG monitored data collection, revised and validated the paper. TN: monitored data collection, revised and validated the paper. AM monitored data collection, revised and validated the paper. BP monitored data collection, revised and validated the paper. BAM monitored data collection, revised and validated the paper. BS monitored data collection, wrote the statistical analysis plan, analysed the data, revised and validated the paper. DE monitored data collection, wrote the statistical analysis plan, analysed the data, revised and validated the paper. SP initiated, designed and supervised the study, monitored data collection, wrote the statistical analysis plan, wrote the draft, revised and validated the paper and on behalf of the ULISSE group.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data availability statement Data are available upon reasonable request.

    Linked Articles

    • At a glance
      Highlights from this issue
      Frank Larkin
      British Journal of Ophthalmology 2021; 105 i-ii Published Online First: 23 Jun 2021. doi: 10.1136/bjophthalmol-2021-319810